Adenosine Deaminase-Severe Combined Immunodeficiency Market Forecast Report 2025 – Designed for Product & Growth Teams
This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Adenosine Deaminase-Severe Combined Immunodeficiency industry.
What is the current market size of the adenosine deaminase-severe combined immunodeficiency industry, and what growth rate is it expected to achieve?
The adenosine deaminase-severe combined immunodeficiency market size has grown strongly in recent years. It will grow from $5.57 billion in 2024 to $5.95 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to the increasing prevalence of severe combined immunodeficiency, rising incidence of PID, growing prevalence of immunodeficiencies, increasing healthcare investments, and increasing awareness of immunodeficiencies.
The adenosine deaminase-severe combined immunodeficiency market size is expected to see strong growth in the next few years. It will grow to $7.70 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to the rising prevalence of genetic disorders, rising usage of bone marrow transplantation, increasing demand for non-conditioned stem cell transplantation, increasing prevalence of ADA deficiency, and rising number of adenosine deaminase deficiency (PDA). Major trends in the forecast period include technological advancements, adoption of gene therapy, government initiatives, advanced genetic testing, and advances in biotechnology.
Download Your Free Sample PDF:
What are the major drivers contributing to the growth of the adenosine deaminase-severe combined immunodeficiency market?
The rising prevalence of genetic disorders is expected to propel the growth of the adenosine deaminase-severe combined immunodeficiency market going forward. Genetic disorders refer to medical conditions caused by abnormalities or mutations in an individual's DNA, either inherited or occurring spontaneously. The rising prevalence of genetic disorders is driven by factors such as improved diagnostic technologies, increased awareness, higher parental age, environmental influences, and population growth. The rising prevalence of genetic disorders, particularly in conditions such as adenosine deaminase-severe combined immunodeficiency (ADA-SCID), drives increased demand for advanced diagnostic methods and targeted treatments. For instance, in December 2022, according to a report published by the Department of Health & Social Care (DHSC), a UK-based government department, as of October 2022, around 33,000 whole genome equivalents were sequenced, with an average diagnostic yield of 32%, rising to 61% in specific conditions. Therefore, the rising prevalence of genetic disorders is driving the growth of the adenosine deaminase-severe combined immunodeficiency market.
What are the major market segments driving the growth of the adenosine deaminase-severe combined immunodeficiency industry?
The adenosine deaminase-severe combined immunodeficiency market covered in this report is segmented –
1) By Treatment Type: Enzyme Replacement Therapy (ERT), Gene Therapy, Stem Cell Transplantation, Supportive Care Treatments
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Age Group: Pediatric (Infants and Children), Adults
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Others End-Users
Subsegments:
1) By Enzyme Replacement Therapy (ERT): Adenosine Deaminase Enzyme Replacement, Pegylated Erythropoietin (PEG-EPO)
2) By Gene Therapy: Autologous Stem Cell-Based Gene Therapy, Viral Vector-Mediated Gene Therapy
3) By Stem Cell Transplantation: HLA-Matched Bone Marrow Transplant, Umbilical Cord Blood Transplant
4) By Supportive Care Treatments: Antimicrobial Therapy, Immune System Support, Nutritional Support
View The Full Market Report:
What are the key trends shaping the adenosine deaminase-severe combined immunodeficiency market in the forecast period?
Major companies operating in the adenosine deaminase-severe combined immunodeficiency market are focusing on innovative therapies such as gene therapy for rare diseases to improve treatment outcomes, enhance patient survival, and address the underlying genetic causes of the disorder through advanced medical technologies. Gene therapy in adenosine deaminase-severe combined immunodeficiency (ADA-SCID) aims to correct the genetic defect by introducing a functional copy of the ADA gene, potentially providing a long-term cure for patients with this rare and life-threatening immune disorder. For instance, in May 2022, Danaher Corporation, a US-based life sciences and diagnostics innovator company, joined the Bespoke Gene Therapy Consortium (BGTC) as part of the Accelerating Medicines Partnership (AMP) program. In collaboration with the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), pharmaceutical companies, and non-profit organizations, this initiative aims to advance customized gene therapies for rare diseases and enhance development efficiency. This partnership is particularly significant as it represents a collective effort to address the challenges of traditional drug development for rare diseases—conditions that often receive limited commercial interest due to their low prevalence.
Who are the key market players contributing to the growth of the adenosine deaminase-severe combined immunodeficiency industry?
Major companies operating in the adenosine deaminase-severe combined immunodeficiency market are Novartis AG, GlaxoSmithKline plc (GSK), Astellas Pharma, Orient EuroPharma, Charles River Laboratories, Chiesi Farmaceutici S.p.A., Spark Therapeutics, Rocket Pharmaceuticals, Bluebird Bio, Ospedale San Raffaele (OSR), Oxford Biomedica PLC, Teijin Pharma, Leadiant Biosciences, Orchard Therapeutics PLC, Fondazione Telethon, Mustang Bio Inc, Sigma-Tau Pharmaceuticals, Shenzhen Geno-Immune Medical Institute, ENZON Pharmaceuticals, QED Bioscience Inc.
Which regions are leading the growth of the adenosine deaminase-severe combined immunodeficiency market globally?
North America was the largest region in the adenosine deaminase-severe combined immunodeficiency market in 2024. The regions covered in the adenosine deaminase-severe combined immunodeficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Adenosine Deaminase-Severe Combined Immunodeficiency Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
Need Customized Data On Adenosine Deaminase-Severe Combined Immunodeficiency Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment